Jefferies Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen: 'We view yesterday's announcement as highly positive for PRAX'
December 31, 2025 7:16 AM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $353.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Yesterday AM, PRAX announced it was granted Breakthrough Designation (BTD) for ulixa in Essential Tremor (ET). As a reminder, per the FDA website, BTD is a process designed to expedite the development and review of drugs... More
